ReviewJournal of neurology2023
Migraine: from pathophysiology to treatment.
Review in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06212869 (Green Light and Transcranial Direct Current Stimulation in Migraine Patients; a Randomized Control Trial.), which is not on this map. Cited by 103 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Green Light and Transcranial Direct Current Stimulation in Migraine Patients; a Randomized Control Trial.
Who cites it
103 citing papers in PubMed, 5 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Prophylactic efficacy and safety of valproate versus topiramate for migraine: a systematic review.BMC neurology · 2026Pooled it
- Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis.Headache · 2026Pooled it
- "The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials".BMC neurology · 2025Pooled it
- Spinal manipulations for migraine: an updated systematic review and meta-analysis of randomized clinical trials.Systematic reviews · 2024Pooled it
- A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: Studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy.Frontiers in neuroendocrinology · 2023Pooled it
- Population Pharmacokinetics of Atogepant for the Prevention of Migraine.Clinical pharmacokinetics · 2026Trial
- Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, in Healthy Chinese Participants.Clinical pharmacology in drug development · 2025Trial
- Monitoring of optic sheath diameter during acute migraine attack: an objective criteria for the severity of disease.Acta neurologica Belgica · 2024Trial
- Concentration-QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval.CPT: pharmacometrics & systems pharmacology · 2024Trial
- Review
- Peripheral CD4 T-Cell State Remodeling in Migraine Revealed by Single-Cell RNA Sequencing.Journal of molecular neuroscience : MN · 2026Article
- Dopaminergic Dysregulation in Migraine: From Hypothalamic A11 Dysfunction to a Systemic Biobehavioral Phenotype.International journal of molecular sciences · 2026Review
- Nose-to-Brain Nanocarriers for Migraine Management: A Comprehensive Review of Drug Delivery Strategies and Translational Challenges.Current medical science · 2026Review
- Pancreatic Steatosis: Innocent Bystander or Silent Culprit?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Evidence of Hypoxia Signaling and Endothelial Activation in Migraine: Relationships Between HIF-1α, VEGF-A, and Arginine Metabolism.Biomedicines · 2026Article
- Serum serotonin and its association with glycaemic indices and haemoglobin in adults with migraine: a comparative cross-sectional study.BMC neurology · 2026Observational
- Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Novel Potential Risk Loci for Migraine in the Portuguese Population.International journal of molecular sciences · 2026Article
- Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans.Clinical and translational science · 2026Article
- Oxidative Stress in Migraine-Effect or Cause?Genes · 2026Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is an extremely disabling, common neurological disorder characterized by a complex neurobiology, involving a series of central and peripheral nervous system areas and networks. A growing increase in the understanding of migraine pathophysiology in recent years has facilitated translation of that knowledge into novel treatments, which are currently becoming available to patients in many parts of the world and are substantially changing the clinical approach to the disease. In the first part of this review, we will provide an up to date overview of migraine pathophysiology by analyzing the anatomy and function of the main regions involved in the disease, focusing on how these give rise to the plethora of symptoms characterizing the attacks and overall disease. The second part of the paper will discuss the novel therapeutic agents that have emerged for the treatment of migraine, including molecules targeting calcitonin gene-related peptide (gepants and monoclonal antibodies), serotonin 5-HT
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.